Paul Baldrick is Executive Director, Nonclinical Regulatory Strategy within the Global Regulatory Affairs Department at Covance; he has a PhD from Durham University, UK. Professor Baldrick is also Visiting Chair (Regulatory Toxicology) of the School of Pharmacy, University of Lincoln, UK. His responsibilities include providing regulatory strategy/preclinical support for new product development/registration of small molecule pharmaceuticals, biotechnology products, vaccines and medical devices.